Vincristine sulfate

Name: Vincristine sulfate
Brand: Selleck Chemicals
SKU: S1241
Rating: 5 (73 reviews)

For research use only.

Catalog No.S1241 Synonyms: Leurocristine

73 publications

CAS No. 2068-78-2

Vincristine sulfate (Leurocristine) is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay. Vincristine sulfate induces apoptosis.

Selleck's Vincristine sulfate has been cited by 73 publications

Cancer Discov, 2019, 9(2):230-247

PubMed: 30373918 ( click the link to review the publication )

Cancer Cell, 2017, 31(6):833-843

PubMed: 28552327 ( click the link to review the publication )

Cancers (Basel), 2021, 13(2)E361

PubMed: 33478100 ( click the link to review the publication )

Invest New Drugs, 2021, 10.1007/s10637-020-01003-3

PubMed: 33475937 ( click the link to review the publication )

Toxicol Lett, 2021, 340:67-76

PubMed: 33429010 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432.CCR-20-1315

PubMed: 32826328 ( click the link to review the publication )

Oncogene, 2020, 39(17):3555-3570

PubMed: 32123312 ( click the link to review the publication )

Environ Sci Technol, 2020, 54(23):15267-15276

PubMed: 33201683 ( click the link to review the publication )

Cancer Lett, 2020, 469:111-123

PubMed: 31639426 ( click the link to review the publication )

J Pathol, 2020, 10.1002/path.5591

PubMed: 33206391 ( click the link to review the publication )

BMC Biol, 2020, 22;18(1):42

PubMed: 32321486 ( click the link to review the publication )

Arch Toxicol, 2020, 10.1007/s00204-020-02933-w

PubMed: 33057863 ( click the link to review the publication )

Mol Cancer Ther, 2020, 25;molcanther.1021.2019

PubMed: 32451331 ( click the link to review the publication )

Aging (Albany NY), 2020, 12(23):24424-24440

PubMed: 33291076 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(8):2649-2676

PubMed: 32905466 ( click the link to review the publication )

PLoS Negl Trop Dis, 2020, 17;14(4):e0008224

PubMed: 32302296 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Toxicology, 2020, 429:152329

PubMed: 31733235 ( click the link to review the publication )

Vet Comp Oncol, 2020, 10.1111/vco.12656

PubMed: 33025640 ( click the link to review the publication )

Biol Open, 2020, bio.050211

PubMed: 33372065 ( click the link to review the publication )

Cell Biol Int, 2020, 44(2):610-620

PubMed: 31743535 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Mol Med Rep, 2020, 22(4):2791-2800

PubMed: 32945456 ( click the link to review the publication )
Neuroreport, 2020, 31(3):197-204

PubMed: 31834144 ( click the link to review the publication )

Int J Cancer, 2020, 10.1002/ijc.33202

PubMed: 32638373 ( click the link to review the publication )

Sci Rep, 2020, 10(1):13124

PubMed: 32753665 ( click the link to review the publication )

J Hematol Oncol, 2020, 13(1):95

PubMed: 32677976 ( click the link to review the publication )

Int J Med Sci, 2020, 17(11):1652-1664

PubMed: 32669967 ( click the link to review the publication )

Cancer Res, 2019, 79(20):5382-5393

PubMed: 31405846 ( click the link to review the publication )

Cell Rep, 2019, 27(11):3331-3344

PubMed: 31189115 ( click the link to review the publication )

Cell Rep, 2019, 26(6):1544-1556

PubMed: 30726737 ( click the link to review the publication )

Cell Rep, 2019, 27(2):631-647

PubMed: 30970263 ( click the link to review the publication )

Elife, 2019, 8

PubMed: 31742555 ( click the link to review the publication )

J Lipid Res, 2019, 60(6):1078-1086

PubMed: 30962310 ( click the link to review the publication )

Biochem Pharmacol, 2019, 170:113642

PubMed: 31541631 ( click the link to review the publication )

J Cell Biochem, 2019, 120(10):17791-17810

PubMed: 31264739 ( click the link to review the publication )

Oncotarget, 2019, 10(60):6403-6417

PubMed: 31741706 ( click the link to review the publication )

J Exp Med, 2018, 215(8):2137-2155

PubMed: 30045945 ( click the link to review the publication )

Cell Cycle, 2018, 17(5):652-668

PubMed: 28749250 ( click the link to review the publication )

SLAS Discov, 2018, 23(7):687-696

PubMed: 29865911 ( click the link to review the publication )

J Exp Med, 2018, 215(12):3094-3114

PubMed: 30404791 ( click the link to review the publication )

Oncotarget, 2018, 9(92):36413-36429

PubMed: 30559927 ( click the link to review the publication )

Sci Rep, 2018, 8(1):14421

PubMed: 30258062 ( click the link to review the publication )

Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-1965

PubMed: 30530705 ( click the link to review the publication )

Leukemia, 2018, 32(3):616-625

PubMed: 28904384 ( click the link to review the publication )

Chemosphere, 2018, 210:467-475

PubMed: 30025364 ( click the link to review the publication )

Oncotarget, 2018, 9(10):9273-9284

PubMed: 29507689 ( click the link to review the publication )
Oncol Lett, 2018, 15(5):6107-6114

PubMed: 29731842 ( click the link to review the publication )

Clin Cancer Res, 2017, 15;23(10):2506-2515

PubMed: 27780854 ( click the link to review the publication )

J Cell Biol, 2017, 216(11):3655-3675

PubMed: 28877995 ( click the link to review the publication )

Cell Death Dis, 2017, 8(10):e3062

PubMed: 28981092 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(8):1555-1565

PubMed: 28522589 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(1):3-15

PubMed: 27760837 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 363(1):20-34

PubMed: 28760737 ( click the link to review the publication )

Int J Oncol, 2017, 51(1):257-268

PubMed: 28534954 ( click the link to review the publication )

Oncotarget, 2017, 8(12):18626-18639

PubMed: 28148893 ( click the link to review the publication )

Oncotarget, 2017, 8(24):39064-39076

PubMed: 28388564 ( click the link to review the publication )

Drugs R D, 2017, 17(2):287-296

PubMed: 28299646 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 29245981 ( click the link to review the publication )

Cell Death & Disease, 2017, 10.1038/cddis.2017.454

PubMed: ( click the link to review the publication )

Drug Des Devel Ther, 2017, 11:1335-1351

PubMed: 28496304 ( click the link to review the publication )

BMC Pharmacol Toxicol, 2017, 18(1):63

PubMed: 28877739 ( click the link to review the publication )

ACS Cent Sci, 2016, 2(8):545-59

PubMed: 27610416 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(32):9015-20

PubMed: 27450084 ( click the link to review the publication )

Lipids Health Dis, 2016, 15:152

PubMed: 27613245 ( click the link to review the publication )

Mol Cancer Res, 2016, 14(10):909-919

PubMed: 27358112 ( click the link to review the publication )

Int J Anal Chem, 2015, 2015:743915

PubMed: 27034675 ( click the link to review the publication )

Cell Rep, 2015, 13(11):2353-2361

PubMed: 26686626 ( click the link to review the publication )

J Pharmacol Exp Ther, 2014, 350(3):646-56

PubMed: 24993360 ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Cancer Res, 2013, 73(20):6310-22

PubMed: 24067506 ( click the link to review the publication )
Int J Mol Sci, 2012, 13(9):10736-49

PubMed: 23109819 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Antineoplastic and Immunosuppressive Antibiotics Inhibitors

Biological Activity

Description

Targets

Microtubules ^[1]
(Cell-free assay)

32 μM

In vitro

Vincristine inhibits net addition of tubulin dimers at assembly ends of steady-state microtubules with K_i of 85 nM. ^[1] At low concentrations, Vincristine stabilizes the spindle apparatus resulting in failure of the chromosomes to segregate leading to metaphase arrest and inhibition of mitosis. At higher concentrations, Vincristine may disrupt and induce total depolymerization of microtubules. ^[2] Vincristine induces apoptosis in tumor cells and inhibits SH-SY5Y cell proliferation with IC50 of 0.1 μM. Vincristine induces mitotic arrest and promots the expression of caspase-3 and -9 and cyclin B, while decreasing the expression of cyclin D. ^[4] Vincristine induced neurotoxicity is caused by interference with microtubule function, which results in blockage of axonal transport and thus in axonal degeneration. ^[5]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HepG2.2.15	MVvD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MX:wMVAvPSEQvF2=	NEPwUG4zPCCq		MYHk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>?	NWKxeldDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2OlM4PjlpPkK1OlY{PzZ7PD;hQi=>
HepG2-HBV1.1	MnS3RZBweHSxc3nzJGF{e2G7	NXfNXIdFOC1yLkWg{txO	NHXaTm4zPCCq		NXnuTFVJcW6mdXPld{BieG:ydH;zbZMh\G:\|ZTDk[ZBmdmSnboTsfS=>	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ4M{e2PUc,OjV4NkO3Olk9N2F-
HepG2.2.15	MlTNSpVv[3Srb36gRZN{[Xl?	NV;FbnFDOC5zIN88US=>	MmG0NlQhcA>?		M3v5fZBzd22xdHXzJIhmeGG2aYTpd{BDKH[rcoXzJJBzd3SnaX6g[ZhxemW\|c3nvci=>	NY\tSWRQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2OlM4PjlpPkK1OlY{PzZ7PD;hQi=>
HepG2-HBV1.1	M4HUfmZ2dmO2aX;uJGF{e2G7	NG\nRWwxNjFizszN	M4rjS\|I1KGh?		Mm\LdJJwdW:2ZYOgbIVx[XSrdHnzJGIhfmm{dYOgdJJwfGWrbjDlfJBz\XO\|aX;u	NUDqeYlpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2OlM4PjlpPkK1OlY{PzZ7PD;hQi=>
HepG2-HBV1.1	MXzGeY5kfGmxbjDBd5NigQ>?	M3f2NFAvOSEQvF2=	NVHsdJB5PDhiaB?=		MXfwdo9ud3SnczDj[YxtKGW6Y4LleIlwdiCxZjDo[ZBifGm2aYOgRkB3cXK3czDueYNt\W:lYYDzbYR{KGmwc4TlZYQhd2ZiaHXwZZRqfGm\|IFKgeolzfXNiRHHu[UBx[XK2aXPs[ZM>	M37lWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Nk[zO\|Y6Lz5{NU[2N\|c3QTxxYU6=
HepG2-HBV1.1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkPCNE4yKM7:TR?=	MUexMVUh\A>?		NV\Yb4NlcW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44hfGmvZTDk[ZBmdmSnboTsfS=>	MmTtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4NkO3OlkoRjJ3Nk[zO\|Y6RC:jPh?=
HepG2-HBV1.1	MmDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn7jNE4yKM7:TR?=	M1e2O\|EuPSCm		NUHxWnp{cW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44hfGmvZTDk[ZBmdmSnboTsfS=>	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ4M{e2PUc,OjV4NkO3Olk9N2F-
HepG2-HBV1.1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV7sUplNOC5zIN88US=>	MWSxNk04OiCq		NInaUJBqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIF1KFNvcHjhd4U>	NEfleno9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[2N\|c3QSd-MkW2OlM4Pjl:L3G+
HepG2-HBV1.1	M4\RVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWSwMlEh\|ryP	NGfEOpIyOi15MjDo		NUnvZnNUcW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBifCCVLYDoZZNm	NXHw[\|c4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2OlM4PjlpPkK1OlY{PzZ7PD;hQi=>
Raji	M2TSN2Z2dmO2aX;uJGF{e2G7	NYnZZY92OC53wrFOwG0>	NID2dIw4OiCq		MoSyZYJwdGm\|aHXzJIF2fG:yaHHnfeKh	NIrifoY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS0OlM4Pyd-MkW0OFY{Pzd:L3G+
SK-MEL-28	NWjzeFVNTnWwY4Tpc44hSXO\|YYm=	NVP2Vm9kOzBibl2=	M3qxelYhcA>?		MX3pcoR2[2W\|IFey5qCUVSClZXzsMYN6[2ynIHHydoV{fA>?	MlTVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV\|MUOwNVAoRjJ3M{GzNFExRC:jPh?=
H157	NW\LbFY5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NW\pOXl[UUN3ME2xMlA{KMLzIECuNFQhdWm3Ml2=	NFLlSVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK1O\|kyOSd-MkWyOVc6OTF:L3G+
Jurkat	Mli0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFfVSW4yNTNibl2=	Mkn6OFjDqGh?	MVvEUXNQ	NWnpZ5Jt\GWlcnXhd4V{KH[rYXLs[UBk\WyuIH71cYJmenNiZH;z[UBl\XCnbnTlcpRtgQ>?	NGnKOWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG1OlE1Pid-MkWxOVYyPDZ:L3G+
CEM	NGHUW2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1vKSVEuOyCwTR?=	MlPZOFjDqGh?	NV:3bIpbTE2VTx?=	NUjDblNM\GWlcnXhd4V{KH[rYXLs[UBk\WyuIH71cYJmenNiZH;z[UBl\XCnbnTlcpRtgQ>?	NFrRe2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG1OlE1Pid-MkWxOVYyPDZ:L3G+
P12	NFzWVnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGPyWFcyNTNibl2=	MYi0POKhcA>?	MoD0SG1UVw>?	MV3k[YNz\WG\|ZYOgeoli[mynIHPlcIwhdnWvYnXyd{Bld3OnIHTldIVv\GWwdHz5	NWrOPHFwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxOVYyPDZpPkK1NVU3OTR4PD;hQi=>
KB	M4H6Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXvJR\|UxRTBwMEC0PUDDuSByLkCwNFEh\|ryP	NYT4[G44RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOVg2OjZpPkK1NFU5PTJ4PD;hQi=>
KBv200 (ABCB1)	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXLHVXhIUUN3ME2wMlM1PjJiwsGgNE4xODZ4IN88US=>	NILuW449[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC1PFUzPid-MkWwOVg2OjZ:L3G+
SUDHL6	NUDoVJVRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2DKXFHjiIoQvF2=	Mle1OFgwPzJiaB?=		Mn;XbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHlic3nncolncWOjboTsfS=>	MmKyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NkG2NFQoRjJ2OU[xOlA1RC:jPh?=
SUDHL6	MYfGeY5kfGmxbjDBd5NigQ>?	M2PXd\|HjiIoQvF2=	NEnyNI84OiCq		M{DpVolv\HWlZYOgd4lodmmoaXPhcpQh[XCxcITveIlkKG2xcoDoc4xw\3liY3jhcodmeyClb4Ty[ZN1\WRid3n0bEBDS0xzMVGgd4lTVkF?	NV7TdlBZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OlE3ODRpPkK0PVYyPjB2PD;hQi=>
HCT-116	M13zVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFvxV4RIUTVyPUWgcm0>	NHTaeJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmyO\|g2Pyd-MkS5Nlc5PTd:L3G+
SKNBe2C	NHn0N3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGT5RolKSzVyPUOyMljDuTRwMDDuUS=>	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl{MUmyNEc,OjR7MkG5NlA9N2F-
IGNR91	NFjXU\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1rSOWlEPTB;MkSuN:KyOS55IH7N	MlHaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MkG5NlAoRjJ2OUKxPVIxRC:jPh?=
SKNAS	M{n1d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1Hnb2lEPTB;MT61xtExNjJibl2=	M4m2SlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUKxPVIxLz5{NEmyNVkzODxxYU6=
LAN1	NVnXSY02T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkTETWM2OD1{LkRCtVAvOiCwTR?=	MnzYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MkG5NlAoRjJ2OUKxPVIxRC:jPh?=
SHSY5Y	NHv4cIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NY[0coRsUUN3ME24MlLDuTBwNjDuUS=>	NGPF[GU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmyNVkzOCd-MkS5NlE6OjB:L3G+
A549-WT	NWf6VIZIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mm[yTWM2OD1zOT60N\|chyrFiMD61PVQhKG6P	MoDqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6NUi4NlcoRjJ2OEW4PFI4RC:jPh?=
A549-R	M{D4ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWfJR\|UxRTF{LkG3PEDDuSByLkOzN{Ahdk1?	NXPUU4d[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4OVg5OjdpPkK0PFU5QDJ5PD;hQi=>
MCF-7-WT	M1POeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3Lv[GlEPTB;MUeuO\|UzKMLzIECuNlE5KCCwTR?=	NYfmeVI3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4OVg5OjdpPkK0PFU5QDJ5PD;hQi=>
MCF-7-R	NGLxeY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWTJR\|UxRTVwNUO5JOKyKDBwMUS0JEBvVQ>?	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh3OEiyO{c,OjR6NUi4Nlc9N2F-
A549-R	M4DQS2N6fG:2b4jpZ4l1gSCDc4PhfS=>				MmnZTWM2OD1zMj6xO\|ghyrFiMD6zN\|Mhdk1?	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh3OEiyO{c,OjR6NUi4Nlc9N2F-
MCF-7-R	M4XvfmN6fG:2b4jpZ4l1gSCDc4PhfS=>				NGi5SHdKSzVyPUWuOVM6KMLzIECuNVQ1KG6P	NXLIcHo5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4OVg5OjdpPkK0PFU5QDJ5PD;hQi=>
SW620	NXjnVWZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmewTWM2OD15LkiwJOKyKDBwMEigcm0>	NIfwbmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEeyOlc{QSd-MkS3NlY4Ozl:L3G+
SW620/AD300	MlzDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1HMW2lEPTB;OUC5MlYxKMLzIEiuPVEhdk1?	Ml;IQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5Mk[3N\|koRjJ2N{K2O\|M6RC:jPh?=
HEK293/pcDNA3.1	NULLUXpMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MljsTWM2OD1zLkS1JOKyKDBwMkCgcm0>	NFX1[lA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEeyOlc{QSd-MkS3NlY4Ozl:L3G+
HEK293/ABCC1	NGLSUHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4rV[mlEPTB;MUmuNlkhyrFiMj6wPEBvVQ>?	NXTFUHNtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3NlY4OzlpPkK0O\|I3PzN7PD;hQi=>
TCC	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M13o[\|I1KGh?		M3PseWlEPTB;N{Cgcm0>	NVfGUHFVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3NVY6PDRpPkK0O\|E3QTR2PD;hQi=>
TCC	NYDuW\|g5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3LEUVQ5KGh?		NHLDSYVKSzVyPUWwJI5O	Mn3aQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5MU[5OFQoRjJ2N{G2PVQ1RC:jPh?=
HepG2/ADM	NV7xUnFRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml7BTWM2OD1{Lke4OlPDuTBwMkO3NUDPxE1?	NILzO5o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEewOFU2Pid-MkS3NFQ2PTZ:L3G+
HepG2	NFrQSY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkDrTWM2OD1yLkCxNVXDuTBwMECxO{DPxE1?	M{XQfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{C0OVU3Lz5{NEewOFU2PjxxYU6=
MCF-7/ADR	MkDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHG4U4tKSzVyPUSuOFgzPsLzMD6yNFcxKM7:TR?=	Ml7BQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5MES1OVYoRjJ2N{C0OVU3RC:jPh?=
MCF-7	NInU[5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M37p[GlEPTB;MD6wNVU6yrFyLkCwOlIh\|ryP	NVHTbo05RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3NFQ2PTZpPkK0O\|A1PTV4PD;hQi=>
A-172	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoTFNE4yyqEQvF2=	M4e3TVI1Nzd{IHi=		NEjU[IZqdmirYnn0d{Bk\WyuIHfyc5d1cCC2aX3lJIRmeGWwZHXueIx6	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV\|MEKzOUc,OjR3M{CyN\|U9N2F-
U-251MG	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIjLN\|cxNjIEoN88US=>	MlH5NlQwPzJiaB?=		NGPsd4ZqdmirYnn0d{Bk\WyuIHfyc5d1cCC2aX3lJIRmeGWwZHXueIx6	M4\rU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUOwNlM2Lz5{NEWzNFI{PTxxYU6=
DLD-1	Ml;NSpVv[3Srb36gRZN{[Xl?	NHXkOngyODBibl2=	MVq0PEBp		MYfwdo9ud3SnczDSWW5ZOyCmZX3leIh6dGG2aX;uxsA>	NVzVTXNvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NFM1PTNpPkK0OFA{PDV\|PD;hQi=>
CCD18Co	NGDuc4hHfW6ldHnvckBCe3OjeR?=	M3nMbVExOCCwTR?=	M3HSelQ5KGh?		MoHDdJJwdW:2ZYOgVnVPYDNiZHXt[ZRpgWyjdHnvcuKh	MlHhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MEO0OVMoRjJ2NECzOFU{RC:jPh?=
DLD-1	NET2S4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MW[wMVExODBibl2=	NEjub5c1QCCq		Mo\xbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:\|ZTDk[ZBmdmSnboTsfS=>	M4DYPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NECzOFU{Lz5{NESwN\|Q2OzxxYU6=
CCD18Co	NEP0foNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnTKNE0yODByIH7N	M2f4[\|Q5KGh?		NVXjdW5DcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>?	NGrReIs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESwN\|Q2Oyd-MkS0NFM1PTN:L3G+
HepG2	NFnUNoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NGDuc4YzPCCq		NX3UN4tyUUN3ME21Nk426oDLzszN	NFnoSlc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO0NVY5QCd-MkSzOFE3QDh:L3G+
HEK293/pcDNA3.1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEX6UlVKSzVyPUCuNFA1yrFyLkCwNFMh\|ryP	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ6NEe4N{c,OjR{OES3PFM9N2F-
HEK293/MRP1	M{m1eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYDEXGJXUUN3ME2wMlA2PcLzMD6wNVIxKM7:TR?=	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ6NEe4N{c,OjR{OES3PFM9N2F-
Ramos	NIfwbmNCeG:ydH;zbZMhSXO\|YYm=	NWfyWnZTOuLCid88US=>	NGjI[ok1QCCq		MXTpcoR2[2W\|IEO0MlYmyrFzLkmyKUBieG:ydH;zbZM>	M1nOcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkW2OFkyLz5{NEK1OlQ6OTxxYU6=
NCI-H1299/pcDNA3	NHXBSG1E\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NFTEfJIxNTJyIH7N	NW[xZotNQTZiaB?=		NFX3RndqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7	M1nPWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUe3NFEzLz5{NEG3O\|AyOjxxYU6=
H1299/ICAM-3	NWPyS\|VXS2WubDDWbYFjcWyrdImgRZN{[Xl?	MnrONE0zOCCwTR?=	Mki4PVYhcA>?		MWjpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6	Ml3ZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzN{ewNVIoRjJ2MUe3NFEzRC:jPh?=
NCI-H1299/pcDNA3	NHjlfI5HfW6ldHnvckBCe3OjeR?=	M2jMbVEwPS9zMD:yNOKhdk1?	NUfZeItZQTZiaB?=		NYnjPGxwcW6mdXPld{BkdGWjdnHn[UBw\iClYYPwZZNmey1\|LDC4MEA6NCCjbnSgVGFTWA>?	NFjBe2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG3O\|AyOid-MkSxO\|cxOTJ:L3G+
H1299/ICAM-3	M4CwRWZ2dmO2aX;uJGF{e2G7	M{DafVEwPS9zMD:yNOKhdk1?	M2nHZlk3KGh?		Mnz1bY5lfWOnczDjcIVifmGpZTDv[kBk[XOyYYPld{0{NCB6LDC5MEBidmRiUFHSVC=>	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF5N{CxNkc,OjRzN{ewNVI9N2F-
W1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NY\BTFZxUUN3ME2wMlAxOzJizszN	NX6xTpl2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOFAyPzZpPkK0NVQxOTd4PD;hQi=>
W1VR	NYTPXGxrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWLJR\|UxRTBwMEW2JO69VQ>?	NVPtV4puRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOFAyPzZpPkK0NVQxOTd4PD;hQi=>
K562	NFPp[ldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUnQc4pIUUN3ME2wMlA{OiEEsTCwMlAxOSBizszN	NYrqR\|JXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxN\|U6OzdpPkK0NVM2QTN5PD;hQi=>
K562/ADR	M2jIUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVXJR\|UxRTNwMk[xJOKyKDBwNEGyJO69VQ>?	NXfCcGtVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxN\|U6OzdpPkK0NVM2QTN5PD;hQi=>
K562	MYnBdI9xfG:\|aYOgRZN{[Xl?	NY\icmpMOC5\|IN88US=>	NXvRN5dXOjRiaB?=		NVzoN\|JjcW6mdXPld{BieG:ydH;zbZMhe2mpbnnmbYNidnSueR?=	Mn;2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzM{W5N\|coRjJ2MUO1PVM4RC:jPh?=
K562/ADR	MmrWRZBweHSxc3nzJGF{e2G7	MV:zJO69VQ>?	MlXKNlQhcA>?		NYDJenE6cW6mdXPld{BieG:ydH;zbZM>	M4m1c\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUO1PVM4Lz5{NEGzOVk{PzxxYU6=
A549	NWjGbnlwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUnJR\|UxRTBwMUCgxtEhOC5yMzFOwG0>	NHrYfmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{m3NVA4PSd-MkO5O\|ExPzV:L3G+
K562	M1PYc2NmdGxiVnnhZoltcXS7IFHzd4F6	M2G1VFMvPzYkgKO2NOKhdk1?	NYjndI16PzMEoHlCpC=>		NUnhfHBIcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?=	MorDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6N{eyNlMoRjJ\|OEe3NlI{RC:jPh?=
lucena	NVe4XXhoS2WubDDWbYFjcWyrdImgRZN{[Xl?	NWOzflJNOy55NfMAl\|YxyqCwTR?=	M1rxZ\|czyqCqwrC=		MoCwco8h\W[oZXP0	NFv2Vnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i3O\|IzOyd-MkO4O\|czOjN:L3G+
FEPS	MofqR4VtdCCYaXHibYxqfHliQYPzZZk>	M2fJeFMvPzYkgKO2NOKhdk1?	NUPSdVdxPzMEoHlCpC=>		M1T0W45wKGWoZnXjeC=>	Ml7PQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6N{eyNlMoRjJ\|OEe3NlI{RC:jPh?=
A2780	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUjJR\|UxRTNwNTDtUS=>	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh{OUKwN{c,OjN6MkmyNFM9N2F-
ACHN	NHfCNppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkjJTWM2ODxyLkGgcW0>	MnjxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6MkmyNFMoRjJ\|OEK5NlA{RC:jPh?=
U-937	NF2zb4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MULJR\|UxRDN2IH7N	NIfPV\|E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{iyPVIxOyd-MkO4NlkzODN:L3G+
Jurkat	M4fzSmFxd3C2b4Ppd{BCe3OjeR?=	NUfydoJsPcLizsznM41tyqB?	M{fVXFI1KGh?		NF3QRZBqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7	M17wW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OEGwOFA6Lz5{M{ixNFQxQTxxYU6=
Jurkat	M2q4b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NITUPFU2yqEQvHevcYzDqA>?	MUGyOEBp		MVHhdpJme3RiSoXyb4F1KGOnbHzzJIlvKEd{L12gdIhie2V?	NU\ibHA{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4NVA1ODlpPkKzPFExPDB7PD;hQi=>
Hep-2	NVnCXHFZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkXTTWM2OD1yLkC0xtExNjBzIN88US=>	Mo\pQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5OEC0NlQoRjJ\|N{iwOFI1RC:jPh?=
Hep-2/v	M4qzUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MojXTWM2OD1zLklCtVAvOjBizszN	NYDmdVBpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3PFA1OjRpPkKzO\|gxPDJ2PD;hQi=>
SGC-7901	M3;EVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVK1UZBzOC1zMDFOwIcwdWx?	NFfUPHYzPC92OD:3NkBp		NILlNIhqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfCCvYX7u[ZI>	NEX5U5k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{e0N\|U4Oid-MkO3OFM2PzJ:L3G+
SGC-7901/VCR	NGfvV5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2P0XVAuOTBizsznM41t	MorvNlQwPDhxN{KgbC=>		NUH6RnJ2cW6qaXLpeJMh[2WubDDndo94fGhiaX6g[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnRibXHucoVz	NVXtcoIzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3OFM2PzJpPkKzO\|Q{PTd{PD;hQi=>
SGC-7901	NGTEXpJCeG:ydH;zbZMhSXO\|YYm=				MWjpcoR2[2W\|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6	NWf4epBYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3OFM2PzJpPkKzO\|Q{PTd{PD;hQi=>
SGC-7901/VCR	MWrBdI9xfG:\|aYOgRZN{[Xl?				MXfpcoR2[2W\|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6	NF3RR2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{e0N\|U4Oid-MkO3OFM2PzJ:L3G+
KB-3-1	MlTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{PMe2lEPTB;MT62OkDDuSByLkG2NkDPxE1?	MlXnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4N{O0OFUoRjJ\|NkezOFQ2RC:jPh?=
KB-C2	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1LjPWlEPTB;MkCyMlU3KMLzIESyMlQ5OSEQvF2=	Mke0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4N{O0OFUoRjJ\|NkezOFQ2RC:jPh?=
KB-3-1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX3YfW1IUUN3ME2xMlI3KMLzIECuNFI4KM7:TR?=	M{m5N\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NkezOFQ2Lz5{M{[3N\|Q1PTxxYU6=
KB-V1	NEPJZZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkHmTWM2OD1{MEiuPFUhyrFiMkCuOEDPxE1?	M3L0b\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NkezOFQ2Lz5{M{[3N\|Q1PTxxYU6=
HEK293/pcDNA3.1	NInaWY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGDPUphKSzVyPUK0MlEhyrFiMD6yNFQh\|ryP	NYSyUFV5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2O\|M1PDVpPkKzOlc{PDR3PD;hQi=>
HEK293/ABCB1	M3P6SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYfNdotHUUN3ME2zOVEzNjhiwsGgN\|c5NjN7MTFOwG0>	NV3qPYdnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2O\|M1PDVpPkKzOlc{PDR3PD;hQi=>
A549/EGFP	M1qxXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHrIbI4xNjBzLUGwNFAh\|ryP			MUnJR\|UxRTh4LkegxtEhOjlwMTFOwG0>	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ\|NEK4Nkc,OjN4M{SyPFI9N2F-
A549/Slug	MlvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX7JRmtqOC5yMT2xNFAxKM7:TR?=			MVrJR\|UxRTlwNzFCtUA{NjFizszN	M4DZ[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NkO0NlgzLz5{M{[zOFI5OjxxYU6=
JFCR39	M{flSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4fNTFEhyrWP	M{\rflI1KGh?	NGSxZ2hFVVOR	MWLtZZJs\WSueTDpcoNz\WG\|ZYOgeIhmKG63bXLldkBw\iCJMj;NJJBp[XOnIHPlcIx{	NHKx[2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W5PFI4Pid-MkO1PVgzPzZ:L3G+
A549	M1W3W2Z2dmO2aX;uJGF{e2G7	NYnSR2RqOTByIH7N	NGLlSogyPiCq	NYnENXB{TE2VTx?=	NXP2TYRldGWjZIOgeI8h[SCub4PzJI9nKG2rY4LveJVjfWyncx?=	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV7OEK3Okc,OjN3OUiyO\|Y9N2F-
SGC7901	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXHJR\|UxRTFwMkdihKnDueLCiUCuNVEh\|rypL33s	M2rrdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NU[0OFgzLz5{M{W2OFQ5OjxxYU6=
SGC7901/LV-NC	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NITrSlhKSzVyPUGuO\|fjiIoEsfMAjVAvOTZizsznM41t	M{O2VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NU[0OFgzLz5{M{W2OFQ5OjxxYU6=
SGC7901/LV-SGO1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkW3TWM2OD12LkO25qCKyrIkgJmwMlM4KM7:Zz;tcC=>	NWjQVpRiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1OlQ1QDJpPkKzOVY1PDh{PD;hQi=>
SGC7901/VCR	MonwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVnJR\|U{RTJyLkWz5qCKyrIkgJmxMlk3KM7:Zz;tcC=>	M1zjcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NU[0OFgzLz5{M{W2OFQ5OjxxYU6=
SGC7901/VCR-NC	M{HqO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmTXTWM2OD1zOT64OwKBkcLz4pEJNk4xOSEQvHevcYw>	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV4NES4Nkc,OjN3NkS0PFI9N2F-
SGC7901/VCR-si-SGO1	Mo\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MW\JR\|UxRTZwMUlihKnDueLCiUGuNFMh\|rypL33s	NXL6dmsxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1OlQ1QDJpPkKzOVY1PDh{PD;hQi=>
SGC7901/ADR	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYjJR\|UxRTdwOEZihKnDueLCiUCuOlQh\|rypL33s	M2TCdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NU[0OFgzLz5{M{W2OFQ5OjxxYU6=
SGC7901/ADR-NC	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnjVTWM2OD16Lkmz5qCKyrIkgJmwMlY5KM7:Zz;tcC=>	NYXUXYRPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1OlQ1QDJpPkKzOVY1PDh{PD;hQi=>
SGC7901/ADR-si-SGO1	M1r0Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1npXGlEPTB;Mz60OwKBkcLz4pEJNE4zQSEQvHevcYw>	NHnDW2Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W2OFQ5Oid-MkO1OlQ1QDJ:L3G+
SH-SY5Y	NVnQfZNET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUDWWGQ6OC5yMEGtNVAh\|ryP	NG[1WXIzPCCq		MWDJR\|UxRTBwMUGzxtExNjBzMjFOwG0>	NF7zblQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{GyPVA3PSd-MkOxNlkxPjV:L3G+
SH-SY5Y	Ml;HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV3Cco1xOC5yMEGtNVAh\|ryP	M4rNZVQ5KGh?		M{PmXmlEPTB;MD6wO\|jDuTBwMEC5JO69VQ>?	M4f6PVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MUK5NFY2Lz5{M{GyPVA3PTxxYU6=
SH-SY5Y	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml3TNE4xODFvMUCg{txO	M4DMNVczKGh?		M1[5SWlEPTB;MD6wOVHDuTBwMEC4JO69VQ>?	MonVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNzMkmwOlUoRjJ\|MUK5NFY2RC:jPh?=
SH-SY5Y	M3G5fmFxd3C2b4Ppd{BCe3OjeR?=	MlfZNE4yKM7:TR?=	Mnz0NE0zPCCq		MoHUbY5lfWOnczDhdI9xfG:\|aYOgc4YhW0hvU2m1XUBk\WyuczDmc4xtd3erbnegZ4VtdCCleXPs[UBienKnc4SgZZQhfGinIFeyM20heGijc3W=	M2[1ZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MUK5NFY2Lz5{M{GyPVA3PTxxYU6=
SH-SY5Y	NUW4blFESXCxcITvd4l{KEG\|c3H5	MmjMNE4yKM7:TR?=	MoDLNE0zPCCq		NVL5XY96cW6mdXPld{BucXSxdHnjJIFzemW\|dNMg	NYPBe282RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOxNlkxPjVpPkKzNVI6ODZ3PD;hQi=>
LNCAP	Mn3OR5l1d3SxeHnjbZR6KGG\|c3H5		NGfZcXU4OiCqcoO=		MnXLR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUG5ESVBiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JIFt[W2jcjDicJVmKGG\|c3H5MEBKSzVyIE2gNE4xODJ7IN88UU4>	NXuxRYt1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC3N\|I5ODlpPkKwO\|MzQDB7PD;hQi=>
LNCAP	MlL2R5l1d3SxeHnjbZR6KGG\|c3H5		MmPOO\|IhcHK\|		NGfCUlBEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBNVkODUDDj[YxteyCjZoTldkA4OiCqcoOgZpkh[WyjbXHyJIJtfWViYYPzZZktKEmFNUCgQUAxNjByNkGg{txONg>?	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJzNUO0PEc,OjN{MUWzOFg9N2F-
PC3	NHvMPW9EgXSxdH;4bYNqfHliYYPzZZk>		M{\hUlczKGi{cx?=		NF2wOpREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRSzNiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JIFt[W2jcjDicJVmKGG\|c3H5MEBKSzVyIE2gNE4xOTFizszNMi=>	NVHud4c{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC3N\|I5ODlpPkKwO\|MzQDB7PD;hQi=>
PC3	NH[2bWhEgXSxdH;4bYNqfHliYYPzZZk>		NIO4Z5Y4OiCqcoO=		NFewfWhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRSzNiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JIFt[W2jcjDicJVmKGG\|c3H5MEBKSzVyIE2gNE4xOTVizszNMi=>	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJzNUO0PEc,OjN{MUWzOFg9N2F-
PC3	NUDOXIRJS3m2b4TvfIlkcXS7IHHzd4F6		MoPuO\|IhcHK\|		NWi0cox2S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWEN\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4Yh[2WubDD2bYFjcWyrdImgZYZ1\XJiN{KgbJJ{KGK7IHHsZY1ieiCkbIXlJIF{e2G7LDDJR\|UxKD1iMD6wNVU{KM7:TT6=	NYPpR\|Q2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0PFkzQTFpPkKzOFg6OjlzPD;hQi=>
NFF	MUTDfZRwfG:6aXPpeJkh[XO\|YYm=		NULuNIFjPzJiaILz		MVHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOSmYh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkh[WyjbXHyJIJtfWViYYPzZZktKEmFNUCgQUAxNjBzNkmg{txONg>?	M1PYW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEi5NlkyLz5{M{S4PVI6OTxxYU6=
NFF	NXHmWmFIS3m2b4TvfIlkcXS7IHHzd4F6		MUC3NkBpenN?		MnHXR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUmZHKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDhcIFu[XJiYnz1[UBie3OjeTygTWM2OCB;IECuNFE4KM7:TT6=	NWTxOVlIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyNVU{PDhpPkKzNlE2OzR6PD;hQi=>
A549	MkHmR5l1d3SxeHnjbZR6KGG\|c3H5		MkfEO\|IhcHK\|		NX;DRVFXS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjZoTldkA4OiCqcoOgZpkh[WyjbXHyJIJtfWViYYPzZZktKEmFNUCgQUAxNjB{IN88UU4>	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJzNUO0PEc,OjN{MUWzOFg9N2F-
KB	NIXGXJdEgXSxdH;4bYNqfHliYYPzZZk>		M4\J[FczKGi{cx?=		MXTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDLRkBk\WyuczDh[pRmeiB5MjDodpMh[nliU2LCJIF{e2G7LDDJR\|UxKD1iMD6wNkDPxE1w	NYDyUllYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1NlI6PTNpPkK2OVIzQTV\|PD;hQi=>
PC3	M4fjU2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		MkLXOFghcHK\|		MWnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFCFMzDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOC5yMke2JO69VS5?	MlrhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhyM{izNlMoRjJ6MEO4N\|I{RC:jPh?=
HEK	MnPCR5l1d3SxeHnjbZR6KGG\|c3H5		NWfROJhbPzJiaILz		NH;5PZREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJTUtiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JIFt[W2jcjDicJVmKGG\|c3H5MEBKSzVyIE2gNE4xOzFizszNMi=>	MluwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{MUWzOFgoRjJ\|MkG1N\|Q5RC:jPh?=
HeLa	MnnaR5l1d3SxeHnjbZR6KGG\|c3H5		Mm\tO\|IhcHK\|		MlfDR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVN[SClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJINmdGxidnnhZoltcXS7IHHmeIVzKDd{IHjyd{BjgSCjbHHtZZIh[my3ZTDhd5NigSxiSVO1NEA:KDBwMEO1PEDPxE1w	MlfKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2OEmyPVEoRjJ\|NEi5NlkyRC:jPh?=
HeLa	MVXDfZRwfG:6aXPpeJkh[XO\|YYm=		NHXEN5Y4OiCqcoO=		MnKwR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVN[SClZXzsd{Bi\nSncjC3NkBpenNiYomgZYxidWG{IHLseYUh[XO\|YYmsJGlEPTBiPTCwMlA{PiEQvF2u	NH7jOVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{KxOVM1QCd-MkOyNVU{PDh:L3G+
BT549	MYXBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MXO0PEBpenN?		M173NWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQmS1OFkh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNFU1PzJizszNMi=>	NH;VVI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OECzPFMzOyd-MkiwN\|g{OjN:L3G+
DU145	MlniRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M4LpUlQ5KGi{cx?=		MW\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKESXMUS1JINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkC3NlMh\|ryPLh?=	NIXNWpI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OECzPFMzOyd-MkiwN\|g{OjN:L3G+
Leukemia cells	Mn72RY51cXS3bX;yJIF{e2G7		NHS3dGc1QCCqcoO=		MXXBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCOZYXr[Y1q[SClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG\|c3H5MEBIUTVyIE2gNE4yKM7:TT6=	NF\wVYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUCwOlI5PSd-MUmwNFYzQDV:L3G+
Leukemia cells	NEfZNGpCdnSrdIXtc5Ih[XO\|YYm=		NXvsbG5OPDhiaILz		NGHhZoVCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDM[ZVs\W2rYTDj[YxteyCjZoTldkA1QCCqcoOgZpkhW1KEIHHzd4F6NCCJSTC9JFAvOSEQvF2u	MoLiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlyME[yPFUoRjF7MEC2Nlg2RC:jPh?=
Colon cancer cells	MmT4R5l1d3SxeHnjbZR6KGG\|c3H5				MlLpR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gZ49td25iY3HuZ4VzKGOnbHzzMEBIUTVyIE2gNE4yKM7:TT6=	M3HzeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NUm4NFE5Lz5zOEW5PFAyQDxxYU6=
Leukemia cells	Mmi2R5l1d3SxeHnjbZR6KGG\|c3H5				MX3DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDs[ZVs\W2rYTDj[YxteyxiR1m1NEA:KDBwMTFOwG0v	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDV7OECxPEc,OTh3OUiwNVg9N2F-
Colon cancer cells	NXPYeW5iSW62aYT1cY9zKGG\|c3H5		NX7kNpM{PDhiaILz		NF7PS4pCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDDc4xwdiClYX7j[ZIh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IGPSRkBie3OjeTygS2k2OCB;IECuNUDPxE1w	NEW2e5k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUCwOlI5PSd-MUmwNFYzQDV:L3G+
Colon cancer cells	NV7YfIRMSW62aYT1cY9zKGG\|c3H5		NVnGfpM4PDhiaILz		MUfBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCFb3zvckBk[W6lZYKgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSxiR1mgQUAxNjFizszNMi=>	NHGwfmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUCwOlI5PSd-MUmwNFYzQDV:L3G+
Leukemia cells	MUPBcpRqfHWvb4KgZZN{[Xl?				M4HvZWFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIxmfWunbXnhJINmdGy\|LDDHTVUxKD1iMD6xJO69VS5?	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV3OUKwOUc,OTd3NUmyNFU9N2F-
Colon cancer cells	NGn2[\|VCdnSrdIXtc5Ih[XO\|YYm=				NHe2[4pCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBkd2yxbjD0eY1weiClZXzsd{whT0l3MDC9JFAvOSEQvF2u	MonUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd3NUmyNFUoRjF5NUW5NlA2RC:jPh?=
Leukemia cells	M3nPS2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NUHFeYZ4PDhiaILz		MWnHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDs[ZVs\W2rYTDj[YxteyCjZoTldkA1QCCqcoOsJGdKPTBiPTCwMlEh\|ryPLh?=	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODZ6NEW5PUc,OjB4OES1PVk9N2F-
Colon cancer cells	M{XyPWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NYnpV5pYPDhiaILz		NVixRpdiT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4h[2:ub36gZ4Fv[2W{IHPlcIx{KGGodHXyJFQ5KGi{czygS2k2OCB;IECuNUDPxE1w	M4XJWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNki0OVk6Lz5{ME[4OFU6QTxxYU6=
Leukemia cells	MlL5R5l1d3SxeHnjbZR6KGG\|c3H5		NYT1SZVJPDhiaILz		MlzxR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gcIV2c2WvaXGgZ4VtdHNiYX\0[ZIhPDhiaILzMEBIUTVyIE2gNE4yKM7:TT6=	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd2N{e0PUc,OjR5NEe3OFk9N2F-
Colon cancer cells	MUjDfZRwfG:6aXPpeJkh[XO\|YYm=		MnrZOFghcHK\|		NGG2[nlEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBkd2yxbjDjZY5k\XJiY3XscJMh[W[2ZYKgOFghcHK\|LDDHTVUxKD1iMD6xJO69VS5?	MkHpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5NEe3OFkoRjJ2N{S3O\|Q6RC:jPh?=
Leukemia cells	MoP0R5l1d3SxeHnjbZR6KGG\|c3H5		NVnYSldzPDhiaILz		M2XaOGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJIxmfWunbXnhJINmdGy\|IHHmeIVzKDR6IHjyd{whT0l3MDC9JFAvOSEQvF2u	NVTafmdFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyPFM1OzBpPkKyNlg{PDNyPD;hQi=>
Colon cancer cells	NVHmdI53S3m2b4TvfIlkcXS7IHHzd4F6		NXLMPFJbPDhiaILz		M{fSdWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGNQVE:QIHPlcIx{KGGodHXyJFQ5KGi{czygS2k2OCB;IECuNUDPxE1w	MmXMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{OEO0N\|AoRjJ{MkizOFMxRC:jPh?=
MDA-MB-231	MU\BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NGHpSYk1QCCqcoO=		M3vsRWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVTBMW1DNTJ\|MTDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOC5zMU[2JO69VS5?	M1PrflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MEO4N\|I{Lz5{OECzPFMzOzxxYU6=
central nervous system cancer cells	MlLzR5l1d3SxeHnjbZR6KGG\|c3H5				MYLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDj[Y51emGuIH7ldpZwfXNic4nzeIVuKGOjbnPldkBk\WyuczygS2k2OCB;IECuNVI2QDlizszNMi=>	M{LvfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NUm4NFE5Lz5zOEW5PFAyQDxxYU6=
prostate cancer cells	NFv2eYlEgXSxdH;4bYNqfHliYYPzZZk>				NWHYc2hQS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4heHKxc4TheIUh[2GwY3XyJINmdGy\|LDDHTVUxKD1iMD6xNlU5QSEQvF2u	NYHUZmxnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1PVgxOThpPkG4OVk5ODF6PD;hQi=>
CNS	NETxOHVCdnSrdIXtc5Ih[XO\|YYm=		MX:0PEBpenN?		NUHvdpBkSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gR25UKGOjbnPldkBk\WyuczDh[pRmeiB2ODDodpMh[nliU2LCJIF{e2G7LDDHTVUxKD1iMD6xNlU5QSEQvF2u	NVHLc25{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmwNFYzQDVpPkG5NFA3Ojh3PD;hQi=>
prostate cancer cells	M1T4cmFvfGm2dX3vdkBie3OjeR?=		NF3iNZQ1QCCqcoO=		M3O5cWFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIIDyc5N1[XSnIHPhcoNmeiClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG\|c3H5MEBIUTVyIE2gNE4yOjV6OTFOwG0v	NH7s[4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUCwOlI5PSd-MUmwNFYzQDV:L3G+
CNS	MWnBcpRqfHWvb4KgZZN{[Xl?				NEPxZ4xCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBEVlNidIXtc5Ih[2WubIOsJGdKPTBiPTCwMlEzPTh7IN88UU4>	NXftUmVVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1OVkzODVpPkG3OVU6OjB3PD;hQi=>
prostate cancer cells	MnnORY51cXS3bX;yJIF{e2G7				NYH6dZFjSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QheHKxc4TheIUhfHWvb4KgZ4VtdHNuIFfJOVAhRSByLkGyOVg6KM7:TT6=	NWLETpZ6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1OVkzODVpPkG3OVU6OjB3PD;hQi=>
CNS	M1;uPWFvfGm2dX3vdkBie3OjeR?=		MX20PEBpenN?		MkTNRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQ17TJINidmOncjDj[YxteyCjZoTldkA1QCCqcoOgZpkhW1KEIHHzd4F6NCCJSTC9JFAvOTNizszNMi=>	M1zX[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MEC2Nlg2Lz5zOUCwOlI5PTxxYU6=
prostate cancer cells	NIrwO\|BCdnSrdIXtc5Ih[XO\|YYm=		M1jNclQ5KGi{cx?=		NHvTXZhCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDwdo9{fGG2ZTDjZY5k\XJiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JHNTSiCjc4PhfUwhT0liPTCwMlE{KM7:TT6=	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTByNkK4OUc,OTlyME[yPFU9N2F-
prostate cancer cells	NFuz[5lIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NVTiZokzPDhiaILz		NWj3eIpnT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4heHKxc4TheIUh[2GwY3XyJINmdGy\|IHHmeIVzKDR6IHjyd{whT0l3MDC9JFAvOTNizszNMi=>	NGXHN\|E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{ME[4OFU6QSd-MkC2PFQ2QTl:L3G+
CNS	MmKzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NFP6cZM1QCCqcoO=		NXvBVWNIT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hS06VIHPhcoNmeiClZXzsd{Bi\nSncjC0PEBpenNuIFfJOVAhRSByLkGzJO69VS5?	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODZ6NEW5PUc,OjB4OES1PVk9N2F-
CNS	MnzlR5l1d3SxeHnjbZR6KGG\|c3H5		NVnDe29IPDhiaILz		M{j6WmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGNPWyClYX7j[ZIh[2WubIOgZYZ1\XJiNEigbJJ{NCCJSUWwJF0hOC5zMzFOwG0v	M2\CbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{S3O\|Q6Lz5{NEe0O\|c1QTxxYU6=
prostate cancer cells	NHPEcotEgXSxdH;4bYNqfHliYYPzZZk>		MnjMOFghcHK\|		NFPXcldEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBxem:\|dHH0[UBk[W6lZYKgZ4VtdHNiYX\0[ZIhPDhiaILzMEBIUTVyIE2gNE4yOyEQvF2u	MlLUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5NEe3OFkoRjJ2N{S3O\|Q6RC:jPh?=
prostate cancer cells	NHT1U2JEgXSxdH;4bYNqfHliYYPzZZk>		NHXD[GU1QCCqcoO=		MUnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDwdo9{fGG2ZTDjZY5k\XJiY3XscJMh[W[2ZYKgOFghcHK\|LDDHTVUxKD1iMD6xN{DPxE1w	M1nqfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MkizOFMxLz5{MkK4N\|Q{ODxxYU6=
CNS	NWrC[mpPS3m2b4TvfIlkcXS7IHHzd4F6		MkixOFghcHK\|		M37CPWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGNPWyClYX7j[ZIh[2WubIOgZYZ1\XJiNEigbJJ{NCCJSUWwJF0hOC5zMzFOwG0v	NXfOfY5uRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyPFM1OzBpPkKyNlg{PDNyPD;hQi=>
Melanoma cells	NIXlNmNCdnSrdIXtc5Ih[XO\|YYm=		NEHYOFU1QCCqcoO=		M{fw[GFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3lcIFvd22jIHPlcIx{KGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZktKEeLNUCgQUAxNjF3OES5JO69VS5?	NI\0R\|I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUCwOlI5PSd-MUmwNFYzQDV:L3G+
Melanoma cells	MUHDfZRwfG:6aXPpeJkh[XO\|YYm=				M3Tre2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJI1mdGGwb33hJINmdGy\|LDDHTVUxKD1iMD6xOVg1QSEQvF2u	MnzqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3OUiwNVgoRjF6NUm4NFE5RC:jPh?=
Melanoma cells	MU\BcpRqfHWvb4KgZZN{[Xl?				MorXRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgcYVt[W6xbXGgZ4VtdHNuIFfJOVAhRSByLkG1PFQ6KM7:TT6=	NWTZN\|NtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1OVkzODVpPkG3OVU6OjB3PD;hQi=>
Melanoma cells	M1OydWFvfGm2dX3vdkBie3OjeR?=		NGPZeXY1QCCqcoO=		NFvLfoFCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDN[Yxidm:vYTDj[YxteyCjZoTldkA1QCCqcoOgZpkhW1KEIHHzd4F6NCCJSTC9JFAvOTZizszNMi=>	Mom4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlyME[yPFUoRjF7MEC2Nlg2RC:jPh?=
Melanoma cells	M4XH[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7				NVHJXYppT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hdWWuYX7vcYEh[2WubIOgZYZ1\XJiNEigbJJ{NCCJSUWwJF0hOC5zNjFOwG0v	NGPDS2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{ME[4OFU6QSd-MkC2PFQ2QTl:L3G+
Melanoma cells	MmjWR5l1d3SxeHnjbZR6KGG\|c3H5		MVW0PEBpenN?		M1\kZWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJI1mdGGwb33hJINmdGy\|IHHmeIVzKDR6IHjyd{whT0l3MDC9JFAvOTZizszNMi=>	MojLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5NEe3OFkoRjJ2N{S3O\|Q6RC:jPh?=
Melanoma cells	MorTR5l1d3SxeHnjbZR6KGG\|c3H5		NUjSO4JVPDhiaILz		NXP4O292S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hdWWuYX7vcYEh[2WubIOgZYZ1\XJiNEigbJJ{NCCJSUWwJF0hOC5zNjFOwG0v	NUPkT2Q2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyPFM1OzBpPkKyNlg{PDNyPD;hQi=>
A549	NV;LfW1MSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M{P2elQ5KGi{cx?=		NYfYXY0{SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlE4OTVizszNMi=>	NFHobXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OECzPFMzOyd-MkiwN\|g{OjN:L3G+
NSCLC	NXj2R5h7SW62aYT1cY9zKGG\|c3H5		M1rZdVQ5KGi{cx?=		MXjBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCQU1PMR{Bk\WyuczDh[pRmeiB2ODDodpMh[nliU2LCJIF{e2G7LDDHTUA:KDBwMkWg{txONg>?	NGn0d4Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUCwOlI5PSd-MUmwNFYzQDV:L3G+
NSCLC	NEn2RpdIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NX\2b45rPDhiaILz		MofoS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUnNEVENiY3XscJMh[W[2ZYKgOFghcHK\|LDDHTVUxKD1iMD6yOUDPxE1w	NFjLeJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{ME[4OFU6QSd-MkC2PFQ2QTl:L3G+
NSCLC	NXTFcHptS3m2b4TvfIlkcXS7IHHzd4F6		M{fDeFQ5KGi{cx?=		M4HXemN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG5US0yFIHPlcIx{KGGodHXyJFQ5KGi{czygS2k2OCB;IECuNlUh\|ryPLh?=	NGXjc4o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkK4N\|Q{OCd-MkKyPFM1OzB:L3G+
NSCLC	NH[0XppEgXSxdH;4bYNqfHliYYPzZZk>		MnHsOFghcHK\|		M2PpcmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG5US0yFIHPlcIx{KGGodHXyJFQ5KGi{czygS2k2OCB;IECuNlUh\|ryPLh?=	M2fpfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{S3O\|Q6Lz5{NEe0O\|c1QTxxYU6=
NSCLC	MnnkRY51cXS3bX;yJIF{e2G7				MmLmRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgUnNEVENiY3XscJMtKEeLNUCgQUAxNjJ3MUG5JO69VS5?	M{HmWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NUW5NlA2Lz5zN{W1PVIxPTxxYU6=
NSCLC	MY\BcpRqfHWvb4KgZZN{[Xl?		MkHwOFghcHK\|		NUTHfJhuSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gUnNEVENiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JHNTSiCjc4PhfUwhT0l3MDC9JFAvOjVzMUmg{txONg>?	Mo\HQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlyME[yPFUoRjF7MEC2Nlg2RC:jPh?=
Non-small cell lung carcinoma cells	MXvDfZRwfG:6aXPpeJkh[XO\|YYm=				MUnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOc44ue22jbHygZ4VtdCCudX7nJINiemOrbn;tZUBk\WyuczygS2k2OCB;IECuNlUyOTlizszNMi=>	M{C3cVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NUm4NFE5Lz5zOEW5PFAyQDxxYU6=
ovarian cancer cells	MUTDfZRwfG:6aXPpeJkh[XO\|YYm=				M1T0PGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJI93[XKrYX6gZ4Fv[2W{IHPlcIx{NCCJSUWwJF0hOC5\|MU[yN{DPxE1w	NXzQOnFQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1PVgxOThpPkG4OVk5ODF6PD;hQi=>
renal cancer cells	NV3nSYdES3m2b4TvfIlkcXS7IHHzd4F6				MYHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDy[Y5idCClYX7j[ZIh[2WubIOsJGdKPTBiPTCwMlMyPjJ\|IN88UU4>	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDV7OECxPEc,OTh3OUiwNVg9N2F-
breast cancer cells	M1T2WWN6fG:2b4jpZ4l1gSCjc4PhfS=>				MV\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDidoVie3RiY3HuZ4VzKGOnbHzzMEBIUTVyIE2gNE4{OTZ{MzFOwG0v	M{TUWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NUm4NFE5Lz5zOEW5PFAyQDxxYU6=
ovarian cancer cells	MoS4RY51cXS3bX;yJIF{e2G7		NVXRbnBmPDhiaILz		MXXBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCxdnHybYFvKGOjbnPldkBk\WyuczDh[pRmeiB2ODDodpMh[nliU2LCJIF{e2G7LDDHTVUxKD1iMD6zNVYzOyEQvF2u	NFnuXIY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUCwOlI5PSd-MUmwNFYzQDV:L3G+
renal cancer cells	MlXURY51cXS3bX;yJIF{e2G7		NWPxOHE1PDhiaILz		M13jO2FvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIILlcoFtKGOjbnPldkBk\WyuczDh[pRmeiB2ODDodpMh[nliU2LCJIF{e2G7LDDHTVUxKD1iMD6zNVYzOyEQvF2u	M1nBd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MEC2Nlg2Lz5zOUCwOlI5PTxxYU6=
breast cancer cells	NGrkVY1CdnSrdIXtc5Ih[XO\|YYm=		MnvsOFghcHK\|		M3j0fWFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFLy[YF{fCClYX7j[ZIh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IGPSRkBie3OjeTygS2k2OCB;IECuN\|E3OjNizszNMi=>	NGXDOI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUCwOlI5PSd-MUmwNFYzQDV:L3G+
renal cancer cells	NFvjeYJCdnSrdIXtc5Ih[XO\|YYm=				NVzTfVI1SW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhemWwYXygeJVud3JiY3XscJMtKEeLNUCgQUAxNjNzNkKzJO69VS5?	NWC5NWdHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1OVkzODVpPkG3OVU6OjB3PD;hQi=>
ovarian cancer cells	MkjGRY51cXS3bX;yJIF{e2G7				NFTEVHVCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBwfmG{aXHuJJR2dW:{IHPlcIx{NCCJSUWwJF0hOC5\|MU[yN{DPxE1w	M3XaXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NUW5NlA2Lz5zN{W1PVIxPTxxYU6=
breast cancer cells	MoXDRY51cXS3bX;yJIF{e2G7				NGq2cGhCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBjemWjc4SgeJVud3JiY3XscJMtKEeLNUCgQUAxNjNzNkKzJO69VS5?	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV3OUKwOUc,OTd3NUmyNFU9N2F-
ovarian cancer cells	M{[4NGFvfGm2dX3vdkBie3OjeR?=		MXS0PEBpenN?		MoDZRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5ib4\hdolidiClYX7j[ZIh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IGPSRkBie3OjeTygS2khRSByLkOyJO69VS5?	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTByNkK4OUc,OTlyME[yPFU9N2F-
renal cancer cells	MXHBcpRqfHWvb4KgZZN{[Xl?		M1\YN\|Q5KGi{cx?=		MmTaRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5icnXuZYwh[2GwY3XyJINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCVUlKgZZN{[XluIFfJJF0hOC5\|MjFOwG0v	NVj5[oN2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmwNFYzQDVpPkG5NFA3Ojh3PD;hQi=>
breast cancer cells	MW\BcpRqfHWvb4KgZZN{[Xl?		NYrOcXVkPDhiaILz		NH;VWG5CdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDCdoVie3RiY3HuZ4VzKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDTVmIh[XO\|YYmsJGdKKD1iMD6zNkDPxE1w	MlfZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlyME[yPFUoRjF7MEC2Nlg2RC:jPh?=
renal cancer cells	NYm3UIpqT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MX[0PEBpenN?		MkPOS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gdoVv[WxiY3HuZ4VzKGOnbHzzJIFnfGW{IES4JIhzeyxiR1m1NEA:KDBwM{Kg{txONg>?	M{SzcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNki0OVk6Lz5{ME[4OFU6QTxxYU6=
breast cancer cells	NXzQOVljT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NGDZ[4g1QCCqcoO=		NYCyVnJ[T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4h[nKnYYP0JINidmOncjDj[YxteyCjZoTldkA1QCCqcoOsJGdKPTBiPTCwMlMzKM7:TT6=	NX\vOmhQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC2PFQ2QTlpPkKwOlg1PTl7PD;hQi=>
ovarian cancer cells	MVTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MXi0PEBpenN?		NX\rRZRvT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hV3[jcnnhckBk[W6lZYKgZ4VtdHNiYX\0[ZIhPDhiaILzMEBIUTVyIE2gNE4{OiEQvF2u	Mnm3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB4OES1PVkoRjJyNki0OVk6RC:jPh?=
breast cancer cells	NF;vWHpEgXSxdH;4bYNqfHliYYPzZZk>		M1XMT\|Q5KGi{cx?=		MnzrR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gZpJm[XO2IHPhcoNmeiClZXzsd{Bi\nSncjC0PEBpenNuIFfJOVAhRSByLkOyJO69VS5?	M{mzPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{S3O\|Q6Lz5{NEe0O\|c1QTxxYU6=
renal cancer cells	NHfRSZlEgXSxdH;4bYNqfHliYYPzZZk>		M2H0elQ5KGi{cx?=		NXvZO4JNS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hemWwYXygZ4Fv[2W{IHPlcIx{KGGodHXyJFQ5KGi{czygS2k2OCB;IECuN\|Ih\|ryPLh?=	MoHOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5NEe3OFkoRjJ2N{S3O\|Q6RC:jPh?=
ovarian cancer cells	M1TPeGN6fG:2b4jpZ4l1gSCjc4PhfS=>		Ml;VOFghcHK\|		NVGwRXdpS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hd3[jcnnhckBk[W6lZYKgZ4VtdHNiYX\0[ZIhPDhiaILzMEBIUTVyIE2gNE4{OiEQvF2u	NGTmd3M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe0O\|c1QSd-MkS3OFc4PDl:L3G+
renal cancer cells	NUKxeIxSS3m2b4TvfIlkcXS7IHHzd4F6		MYi0PEBpenN?		Mn;ER5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gdoVv[WxiY3HuZ4VzKGOnbHzzJIFnfGW{IES4JIhzeyxiR1m1NEA:KDBwM{Kg{txONg>?	NYDtXJNGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyPFM1OzBpPkKyNlg{PDNyPD;hQi=>
ovarian cancer cells	NG[wUpZEgXSxdH;4bYNqfHliYYPzZZk>		Mn;GOFghcHK\|		MmfpR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gc5ZiemmjbjDjZY5k\XJiY3XscJMh[W[2ZYKgOFghcHK\|LDDHTVUxKD1iMD6zNkDPxE1w	NHL1T3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkK4N\|Q{OCd-MkKyPFM1OzB:L3G+
breast cancer cells	Ml3NR5l1d3SxeHnjbZR6KGG\|c3H5		M1u0bFQ5KGi{cx?=		NF[3fI5EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBjemWjc4SgZ4Fv[2W{IHPlcIx{KGGodHXyJFQ5KGi{czygS2k2OCB;IECuN\|Ih\|ryPLh?=	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ6M{SzNEc,OjJ{OEO0N\|A9N2F-
Lu1	NEfad21EgXSxdH;4bYNqfHliYYPzZZk>		MUW3NkBpenN?		NW\mNFFMS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVHVzIHPlcIx{KGGodHXyJFczKGi{czDifUBUWkJiYYPzZZktKEmFNUCgQUAxNjR6IN88UU4>	MmHFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3MkK5OVMoRjJ4NUKyPVU{RC:jPh?=
MCF7	MWHDfZRwfG:6aXPpeJkh[XO\|YYm=		MnK1O\|IhcHK\|		MlPjR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{Bi\nSncjC3NkBpenNiYomgV3JDKGG\|c3H5MEBKSzVyIE2gNE42OSEQvF2u	MlHBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3MkK5OVMoRjJ4NUKyPVU{RC:jPh?=
HepG2	NWDxO3k{S3m2b4TvfIlkcXS7IHHzd4F6		MlLWO\|IhcHK\|		MYjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{Bi\nSncjC3NkBpenNiYomgV3JDKGG\|c3H5MEBKSzVyIE2gNE43QSEQvF2u	M36zN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NUKyPVU{Lz5{NkWyNlk2OzxxYU6=
COLON	NFznSWhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MXu0PEBpenN?		NHzj[oFIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBkd2yxbjDjZY5k\XJiY3XscJMh[W[2ZYKgOFghcHK\|LDDUS2khRSB\|Lkm4JO69VS5?	NIThSpA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{ME[4OFU6QSd-MkC2PFQ2QTl:L3G+
COLON	NGfYTZFEgXSxdH;4bYNqfHliYYPzZZk>		NF3XbJQ1QCCqcoO=		NETNRmtEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBkd2yxbjDjZY5k\XJiY3XscJMh[W[2ZYKgOFghcHK\|LDDUS2khRSB\|Lkm4JO69VS5?	NYLZfGUyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3OFc4PDlpPkK0O\|Q4PzR7PD;hQi=>
COLON	NX;tNZlpS3m2b4TvfIlkcXS7IHHzd4F6		M2jiR\|Q5KGi{cx?=		NHLHcmREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBEV0yRTjDj[YxteyCjZoTldkA1QCCqcoOsJHRIUSB;IEOuPVgh\|ryPLh?=	NXPydnhLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyPFM1OzBpPkKyNlg{PDNyPD;hQi=>
COLON	MlHuR5l1d3SxeHnjbZR6KGG\|c3H5				MkTlR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gZ49td25iY3HuZ4VzKGOnbHzzMEBVT0liPTCzMlk5OTB5IN88UU4>	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDV7OECxPEc,OTh3OUiwNVg9N2F-
COLON	NFfEbVJCdnSrdIXtc5Ih[XO\|YYm=		M3qxOFQ5KGi{cx?=		MUPBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCFb3zvckBk[W6lZYKgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSxiVFfJJF0hOy57OEGwO{DPxE1w	NU\y[XZrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmwNFYzQDVpPkG5NFA3Ojh3PD;hQi=>
COLON	MmrIRY51cXS3bX;yJIF{e2G7				MnrJRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgZ49td25idIXtc5Ih[2WubIOsJHRIUSB;IEOuPVgyODdizszNMi=>	M{LIR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NUW5NlA2Lz5zN{W1PVIxPTxxYU6=
central nervous system cancer cells	MXLDfZRwfG:6aXPpeJkh[XO\|YYm=				M4HxSmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJINmdnS{YXygcoVzfm:3czDzfZN1\W1iY3HuZ4VzKGOnbHzzMEBVT0liPTC2MlMxQTV5IN88UU4>	M{HUOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NUm4NFE5Lz5zOEW5PFAyQDxxYU6=
prostate cancer cells	MVTDfZRwfG:6aXPpeJkh[XO\|YYm=				MXTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDwdo9{fGG2ZTDjZY5k\XJiY3XscJMtKFSJSTC9JFYvOzB7NUeg{txONg>?	NFPZfWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEW5PFAyQCd-MUi1PVgxOTh:L3G+
CNS	NXv0[nVpSW62aYT1cY9zKGG\|c3H5		M3HBRVQ5KGi{cx?=		NYPTfHl7SW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gR25UKGOjbnPldkBk\WyuczDh[pRmeiB2ODDodpMh[nliU2LCJIF{e2G7LDDUS2khRSB4LkOwPVU4KM7:TT6=	NWO0[2c1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmwNFYzQDVpPkG5NFA3Ojh3PD;hQi=>
prostate cancer cells	NX7MfHFSSW62aYT1cY9zKGG\|c3H5		MUC0PEBpenN?		M1vL[2FvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIIDyc5N1[XSnIHPhcoNmeiClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG\|c3H5MEBVT0liPTC2MlMxQTV5IN88UU4>	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTByNkK4OUc,OTlyME[yPFU9N2F-
CNS	MVHBcpRqfHWvb4KgZZN{[Xl?				NIHjVm5CdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBEVlNidIXtc5Ih[2WubIOsJHRIUSB;IE[uN\|A6PTdizszNMi=>	NYPJSXh[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1OVkzODVpPkG3OVU6OjB3PD;hQi=>
prostate cancer cells	MXjBcpRqfHWvb4KgZZN{[Xl?				MWTBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDwdo9{fGG2ZTD0eY1weiClZXzsd{whXEeLIE2gOk4{ODl3NzFOwG0v	M4rYcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NUW5NlA2Lz5zN{W1PVIxPTxxYU6=
prostate cancer cells	M2XobWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		Mn;pOFghcHK\|		MUjHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDwdo9{fGG2ZTDjZY5k\XJiY3XscJMh[W[2ZYKgOFghcHK\|LDDUS2khRSB4LkOxJO69VS5?	MlPvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB4OES1PVkoRjJyNki0OVk6RC:jPh?=
CNS	M3P6fGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M1;XSVQ5KGi{cx?=		M1H3WWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGNPWyClYX7j[ZIh[2WubIOgZYZ1\XJiNEigbJJ{NCCWR1mgQUA3NjNzIN88UU4>	MnvLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB4OES1PVkoRjJyNki0OVk6RC:jPh?=
CNS	NUjLR3VUS3m2b4TvfIlkcXS7IHHzd4F6		MV20PEBpenN?		MWnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDDUnMh[2GwY3XyJINmdGy\|IHHmeIVzKDR6IHjyd{whXEeLIE2gOk4{OSEQvF2u	NX\Zc\|lzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3OFc4PDlpPkK0O\|Q4PzR7PD;hQi=>
prostate cancer cells	M2HwU2N6fG:2b4jpZ4l1gSCjc4PhfS=>		NWHFPHF[PDhiaILz		MnjqR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gdJJwe3SjdHWgZ4Fv[2W{IHPlcIx{KGGodHXyJFQ5KGi{czygWGdKKD1iNj6zNUDPxE1w	NGjj[2w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe0O\|c1QSd-MkS3OFc4PDl:L3G+
prostate cancer cells	NY\zcFl[S3m2b4TvfIlkcXS7IHHzd4F6		MlPsOFghcHK\|		MWPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDwdo9{fGG2ZTDjZY5k\XJiY3XscJMh[W[2ZYKgOFghcHK\|LDDUS2khRSB4LkOxJO69VS5?	NFPFRVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkK4N\|Q{OCd-MkKyPFM1OzB:L3G+
CNS	MY\DfZRwfG:6aXPpeJkh[XO\|YYm=		NVr2eFR4PDhiaILz		MXXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDDUnMh[2GwY3XyJINmdGy\|IHHmeIVzKDR6IHjyd{whXEeLIE2gOk4{OSEQvF2u	M17I[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MkizOFMxLz5{MkK4N\|Q{ODxxYU6=
Melanoma cells	NWftPGliT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MY[0PEBpenN?		MV;Hdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDt[Yxidm:vYTDj[YxteyCjZoTldkA1QCCqcoOsJHRIUSB;IEeuPVQh\|ryPLh?=	MlPaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB4OES1PVkoRjJyNki0OVk6RC:jPh?=
breast cancer cells	NITkWmpIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M{fOeVQ5KGi{cx?=		NF7WZo1Iem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBjemWjc4SgZ4Fv[2W{IHPlcIx{KGGodHXyJFQ5KGi{czygWGdKKD1iNz65OEDPxE1w	NE[zZZo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{ME[4OFU6QSd-MkC2PFQ2QTl:L3G+
breast cancer cells	NW\6SGw6S3m2b4TvfIlkcXS7IHHzd4F6		Mlr6OFghcHK\|		NVjW[ldOS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4h[nKnYYP0JINidmOncjDj[YxteyCjZoTldkA1QCCqcoOsJHRIUSB;IEeuPVQh\|ryPLh?=	M3vmdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{S3O\|Q6Lz5{NEe0O\|c1QTxxYU6=
Melanoma cells	NVjmZZR3S3m2b4TvfIlkcXS7IHHzd4F6		MVm0PEBpenN?		NUTad2pYS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hdWWuYX7vcYEh[2WubIOgZYZ1\XJiNEigbJJ{NCCWR1mgQUA4Njl2IN88UU4>	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd2N{e0PUc,OjR5NEe3OFk9N2F-
Melanoma cells	M3;KWmN6fG:2b4jpZ4l1gSCjc4PhfS=>		MVO0PEBpenN?		MX7DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDt[Yxidm:vYTDj[YxteyCjZoTldkA1QCCqcoOsJHRIUSB;IEeuPVQh\|ryPLh?=	NHnGdoQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkK4N\|Q{OCd-MkKyPFM1OzB:L3G+
breast cancer cells	MXTDfZRwfG:6aXPpeJkh[XO\|YYm=		Mn\FOFghcHK\|		NYLNNI1US3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4h[nKnYYP0JINidmOncjDj[YxteyCjZoTldkA1QCCqcoOsJHRIUSB;IEeuPVQh\|ryPLh?=	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ6M{SzNEc,OjJ{OEO0N\|A9N2F-
Melanoma cells	NIPYc5ZCdnSrdIXtc5Ih[XO\|YYm=		MoDCOFghcHK\|		M2HHbGFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3lcIFvd22jIHPlcIx{KGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZktKFSJSTC9JFcvQTR\|Mkig{txONg>?	M4PhNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MEC2Nlg2Lz5zOUCwOlI5PTxxYU6=
Melanoma cells	NFHkeHFEgXSxdH;4bYNqfHliYYPzZZk>				NEDPcWxEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBu\Wyjbn;tZUBk\WyuczygWGdKKD1iNz65OFMzQCEQvF2u	NXHTXIx1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1PVgxOThpPkG4OVk5ODF6PD;hQi=>
breast cancer cells	M1fQfGN6fG:2b4jpZ4l1gSCjc4PhfS=>				MkDUR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gZpJm[XO2IHPhcoNmeiClZXzsd{whXEeLIE2gO{46PDN{ODFOwG0v	M2\tRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NUm4NFE5Lz5zOEW5PFAyQDxxYU6=
breast cancer cells	MlT5RY51cXS3bX;yJIF{e2G7		M{fSS\|Q5KGi{cx?=		NYDUN\|AxSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gRpJm[XO2IHPhcoNmeiClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG\|c3H5MEBVT0liPTC3Mlk1OzJ6IN88UU4>	NHXyXmk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUCwOlI5PSd-MUmwNFYzQDV:L3G+
Melanoma cells	NVr6VnBxSW62aYT1cY9zKGG\|c3H5				M4DD[2FvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JI1mdGGwb33hJINmdGy\|LDDUS2khRSB5Lkm0N\|I5KM7:TT6=	M{Dn[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NUW5NlA2Lz5zN{W1PVIxPTxxYU6=
breast tumor cells	MoG2RY51cXS3bX;yJIF{e2G7				MX;BcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDidoVie3RidIXtc5Ih[2WubIOsJHRIUSB;IEeuPVQ{OjhizszNMi=>	NIHGXpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W1PVIxPSd-MUe1OVkzODV:L3G+
NSCLC	MoD1RY51cXS3bX;yJIF{e2G7				NUjLO2NvSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhVlOFTFOgZ4VtdHNuIGTHTUA:KDF3Lki0PFkh\|ryPLh?=	NXziS2Y6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1OVkzODVpPkG3OVU6OjB3PD;hQi=>
Leukemia cells	NVTld2JsSW62aYT1cY9zKGG\|c3H5		MnnOOFghcHK\|		MljJRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTHX1b4VucWFiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JHNTSiCjc4PhfUwhXEeLIE2gNVUvQDR6OTFOwG0v	NFvYU2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUCwOlI5PSd-MUmwNFYzQDV:L3G+
NSCLC	M2nQOmFvfGm2dX3vdkBie3OjeR?=		MUO0PEBpenN?		NG\JZZJCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOV2NNSyClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG\|c3H5MEBVT0liPTCxOU45PDh7IN88UU4>	M1vDVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MEC2Nlg2Lz5zOUCwOlI5PTxxYU6=
Non-small cell lung carcinoma cells	MkezR5l1d3SxeHnjbZR6KGG\|c3H5				M{HDfWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG5wdi2\|bXHscEBk\WyuIHz1coch[2G{Y3nuc41iKGOnbHzzMEBVT0liPTCxOU45PDh7IN88UU4>	NGP4OZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEW5PFAyQCd-MUi1PVgxOTh:L3G+
Leukemia cells	MXrDfZRwfG:6aXPpeJkh[XO\|YYm=				M1j3fGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJIxmfWunbXnhJINmdGy\|LDDUS2khRSBzNT64OFg6KM7:TT6=	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDV7OECxPEc,OTh3OUiwNVg9N2F-
Leukemia cells	MV\BcpRqfHWvb4KgZZN{[Xl?				MWXBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDs[ZVs\W2rYTDj[YxteyxiVFfJJF0hOTVwOES4PUDPxE1w	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV3OUKwOUc,OTd3NUmyNFU9N2F-
NSCLC	M4PjOWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		Ml7TOFghcHK\|		M1;3TGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG5US0yFIHPlcIx{KGGodHXyJFQ5KGi{czygWGdKKD1iMUWuPFUh\|ryPLh?=	M1\iNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNki0OVk6Lz5{ME[4OFU6QTxxYU6=
Leukemia cells	MmT3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NFf5WVg1QCCqcoO=		NX\xTm9uT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hdGW3a3XtbYEh[2WubIOgZYZ1\XJiNEigbJJ{NCCWR1mgQUAyPS56NTFOwG0v	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODZ6NEW5PUc,OjB4OES1PVk9N2F-
NSCLC	NUTtdZNRS3m2b4TvfIlkcXS7IHHzd4F6		MVO0PEBpenN?		NImzXXpEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBPW0OOQzDj[YxteyCjZoTldkA1QCCqcoOsJHRIUSB;IEG1Mlg2KM7:TT6=	NXTYTIF{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyPFM1OzBpPkKyNlg{PDNyPD;hQi=>
Leukemia cells	MoTYR5l1d3SxeHnjbZR6KGG\|c3H5		NWTDO2NEPDhiaILz		NYG1N\|BpS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hdGW3a3XtbYEh[2WubIOgZYZ1\XJiNEigbJJ{NCCWR1mgQUAyPS56NTFOwG0v	M1PxSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{S3O\|Q6Lz5{NEe0O\|c1QTxxYU6=
NSCLC	NHz1ZZREgXSxdH;4bYNqfHliYYPzZZk>		NF31bJU1QCCqcoO=		MkXpR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUnNEVENiY3XscJMh[W[2ZYKgOFghcHK\|LDDUS2khRSBzNT64OUDPxE1w	NUXLSlVsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3OFc4PDlpPkK0O\|Q4PzR7PD;hQi=>
Leukemia cells	MV3DfZRwfG:6aXPpeJkh[XO\|YYm=		M1\0N\|Q5KGi{cx?=		M3y2WGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJIxmfWunbXnhJINmdGy\|IHHmeIVzKDR6IHjyd{whXEeLIE2gNVUvQDVizszNMi=>	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ6M{SzNEc,OjJ{OEO0N\|A9N2F-
renal cancer cells	Ml3hS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NGrQWZo1QCCqcoO=		MUjHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDy[Y5idCClYX7j[ZIh[2WubIOgZYZ1\XJiNEigbJJ{NCCWR1mgQUAyQS57NTFOwG0v	MmnXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB4OES1PVkoRjJyNki0OVk6RC:jPh?=
ovarian cancer cells	M{PSOGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MmDBOFghcHK\|		NY\CdIozT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hV3[jcnnhckBk[W6lZYKgZ4VtdHNiYX\0[ZIhPDhiaILzMEBVT0liPTCxPU46PSEQvF2u	M1;yVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNki0OVk6Lz5{ME[4OFU6QTxxYU6=
renal cancer cells	NFL2dnJEgXSxdH;4bYNqfHliYYPzZZk>		MUC0PEBpenN?		M1PDU2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJJJmdmGuIHPhcoNmeiClZXzsd{Bi\nSncjC0PEBpenNuIGTHTUA:KDF7Lkm1JO69VS5?	Mlu4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5NEe3OFkoRjJ2N{S3O\|Q6RC:jPh?=
ovarian cancer cells	MmHOR5l1d3SxeHnjbZR6KGG\|c3H5		MnOwOFghcHK\|		M3n2[GN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJI93[XKrYX6gZ4Fv[2W{IHPlcIx{KGGodHXyJFQ5KGi{czygWGdKKD1iMUmuPVUh\|ryPLh?=	M3K3fFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{S3O\|Q6Lz5{NEe0O\|c1QTxxYU6=
renal cancer cells	M4G5cGN6fG:2b4jpZ4l1gSCjc4PhfS=>		MYm0PEBpenN?		M4TtVWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJJJmdmGuIHPhcoNmeiClZXzsd{Bi\nSncjC0PEBpenNuIGTHTUA:KDF7Lkm1JO69VS5?	NYHTTIJxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyPFM1OzBpPkKyNlg{PDNyPD;hQi=>
ovarian cancer cells	NE\kV29EgXSxdH;4bYNqfHliYYPzZZk>		MXG0PEBpenN?		NWfxTpZCS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hd3[jcnnhckBk[W6lZYKgZ4VtdHNiYX\0[ZIhPDhiaILzMEBVT0liPTCxPU46PSEQvF2u	NGDOVXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkK4N\|Q{OCd-MkKyPFM1OzB:L3G+
ovarian cancer cells	Mkn5R5l1d3SxeHnjbZR6KGG\|c3H5				NEDJcHREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBwfmG{aXHuJINidmOncjDj[YxteyxiVFfJJF0hOTlwOUWyOkDPxE1w	M2DVW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NUm4NFE5Lz5zOEW5PFAyQDxxYU6=
renal cancer cells	NFLmWZZEgXSxdH;4bYNqfHliYYPzZZk>				M{XlUmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJJJmdmGuIHPhcoNmeiClZXzsd{whXEeLIE2gNVkvQTV{NjFOwG0v	NX3lPHpMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1PVgxOThpPkG4OVk5ODF6PD;hQi=>
ovarian cancer cells	NYHzOpVySW62aYT1cY9zKGG\|c3H5		M1rJSVQ5KGi{cx?=		NHvwTGNCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDveoFzcWGwIHPhcoNmeiClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG\|c3H5MEBVT0liPTCxPU46PTJ4IN88UU4>	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTByNkK4OUc,OTlyME[yPFU9N2F-
renal cancer cells	NU\ZbJJNSW62aYT1cY9zKGG\|c3H5		NFO3fWI1QCCqcoO=		Mn62RY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5icnXuZYwh[2GwY3XyJINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCVUlKgZZN{[XluIGTHTUA:KDF7Lkm1NlYh\|ryPLh?=	NXnXZ2pSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmwNFYzQDVpPkG5NFA3Ojh3PD;hQi=>
renal tumor cells	NXnGOYxKSW62aYT1cY9zKGG\|c3H5				NV\lfmtwSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhemWwYXygeJVud3JiY3XscJMtKFSJSTC9JFE6Njl3Mk[g{txONg>?	MmThQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd3NUmyNFUoRjF5NUW5NlA2RC:jPh?=
ovarian tumor cells	NF:yZVlCdnSrdIXtc5Ih[XO\|YYm=				M1n5cWFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JI93[XKrYX6geJVud3JiY3XscJMtKFSJSTC9JFE6Njl3Mk[g{txONg>?	MmrhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd3NUmyNFUoRjF5NUW5NlA2RC:jPh?=
PC3	NHvxO\|FEgXSxdH;4bYNqfHliYYPzZZk>		NWTnUWdzPDhiaILz		NYDwXVhGS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWEN\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4Yh[2WubDD2bYFjcWyrdImgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEK4MlEyKM7:TT6=	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTF5NEixOkc,OjlzN{S4NVY9N2F-
neural precursor cells	NI\md5VHfW6ldHnvckBie3OjeR?=				NXjoO3dbUW6qaXLpeIlwdiCxZjDu[ZVzd3OyaHXy[UBxem:uaX\ldoF1cW:wIH;mJI1wfXOnIH7leZJidCCycnXjeZJ{d3JiY3XscJMh[nliTWTUJIF{e2G7	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzRzN{[zNUc,OTd2MUe2N\|E9N2F-

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	MPM2 / Cyclin B1 / Cdc25c / p-Cdc2 / Cdc2 / Aurora B / p-H3 / p-PLK1; PubMed: 26156322 J Hematol Oncol MOLT-4 Cells were treated with vincristine (0.3, 1, and 3 nM) alone or co-treated with SAHA (500 nM) for 24 h. Then, total cell lysates were obtained to evaluate the G2/M phase regulatory protein expression and the tubulin acetylation. Data are expressed as mean values ± SD of at least three separate determinations. S SAHA, V vincristine	26156322
Growth inhibition assay	Cell viability ; PubMed: 26156322 J Hematol Oncol MOLT-4 cells were treated with various concentrations of vincristine for 24 and 48 h, respectively. Cell viability was measured by MTT assay.	26156322

In vivo

Vincristine (3 mg/kg) administrated by a single i.p. injection to mice bearing bilateral subcutaneous xenografts Rh12 or Rh18, induces mean growth delay of >120 and >52 day, and repopulating fractions of 0.06% and 5%, respectively. ^[6] Vincristine acts on subcutaneous colon 38 tumors in mice by host cell-mediated vascular effects as well as by direct tubulin-mediated cytotoxicity. Vincristine (5 mg/kg) reduces tumor blood flow of tumors by nearly 75% . ^[7]

Protocol

Cell Research:^[1]

- Collapse

Cell lines: B16 melanoma cell
Concentrations: 10 nM
Incubation Time: 3 days
Method: Cells are plated in 2 mL of medium in 35-mm plates at a concentration of about 5 × 10⁴ cells/mL and grow for 24 h at 37 ℃ in an atmosphere of 5% CO₂ and 95% air. Then medium is replaced with fresh medium lacking or containing 4 nM drug and proliferation is continued for 3 days. Cell counts are done each day in a Coulter Counter after detaching the cells with trypsin and EDTA.
(Only for Reference)

Animal Research:^[6]

- Collapse

Animal Models: Human rhabdomyosarcoma xenografts Rh12
Dosages: 3 mg/kg
Administration: A single i.p. administration
(Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	100 mg/mL (108.33 mM)
	Water	60 mg/mL (65.0 mM)
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): Saline For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Vincristine sulfate SDF

Molecular Weight	923.04
Formula	C₄₆H₅₈N₄O₁₄S
CAS No.	2068-78-2
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	Leurocristine
Smiles	CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04448834	Not yet recruiting	Drug: Blinatumomab	B-cell Acute Lymphoblastic Leukemia	David Rizzieri MD\|Amgen\|Acrotech Biopharma LLC\|Duke University	December 15 2020	Phase 2
NCT03981510	Recruiting	Diagnostic Test: 3D-Transit	Constipation\|Childhood Acute Lymphoblastic Leukemia\|Neurofibromatosis 1\|Chronic Constipation With Overflow	University of Aarhus	June 13 2019	Not Applicable

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I want to use the product #S1421 for mouse in vivo, could you please give us your advice about administration method?
Answer:
According to the reference cited on our website, we test the solubility of S1421 Staurosporine in 4% DMSO/saline, and it is a suspension at 5 mg/mL. The compound can also be dissolved in the vehicle 4% DMSO/30% PEG 300/10% Tween 80/saline at 5 mg/ml as a clear solution for injection.

Choose Your Country or Region

By Signaling Pathways

By product type

Vincristine sulfate